A Study to Evaluate CM336 in Adults with Autoimmune Bullous Disease
NCT ID: NCT06900010
Last Updated: 2025-03-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
30 participants
INTERVENTIONAL
2025-04-01
2027-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease
NCT01024036
Local Spraying of GM-CSF Via Bronchoscopy in the Treatment of Autoimmune Pulmonary Alveolar Proteinosis
NCT06989333
MSC303 Subcutaneous Injection for the Treatment of Immunologic Glomerular Disease.
NCT07000292
A Study of SGB-9768 in Patients with Complement-mediated Kidney Diseases
NCT06786338
Study of Intravenously Administered Anti-LIGHT Monoclonal Antibody CBS001 in Healthy Volunteers
NCT05323110
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention(CM336)
CM336 Injection
subcutaneous CM336 administration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CM336 Injection
subcutaneous CM336 administration
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 2\. Age ≥18 years, regardless of gender；
* 3\. Voluntarily signed informed consent form, with understanding of the study's nature, purpose, procedures, and willingness to comply with trial requirements.
Exclusion Criteria
* 2\. Prior treatment with anti-B-cell maturation antigen (BCMA) therapy；
* 3\. History of allergic reactions to humanized monoclonal antibodies or known allergy to any component of CM336；
* 4\. Any other condition deemed by the investigator to render the subject unsuitable for study participation.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shandong First Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Furen Zhang
Role: PRINCIPAL_INVESTIGATOR
Dermatology Hospital affiliated to Shandong First Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dermatology Hospital Affiliated to Shandong First Medical University
Jinan, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Furen Zhang
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CM336-IIS-PP01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.